Loading stock data…
Ultragenyx Pharmaceutical Inc. (RARE)
$14.88-0.42 (-2.75%)
Market ClosedLast close Sep 8
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ultragenyx Pharmaceutical Inc. in the Healthcare sector is trading at $14.88 with a market capitalization of $1.5B. Wall Street consensus targets $27.00 (19 analysts), implying a +81.5% move over the next 12 months. The stock is currently near its 52-week low of $13.81, remaining 42.6% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +81.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 21) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $214.00M↑ | $136.00M↓ | $207.28M↑ | $159.93M↓ | $167.00M |
| Gross Profit | $180.00M↑ | $106.00M↓ | $177.93M↑ | $131.94M↓ | $144.00M |
| Operating Income | -$75.00M↑ | -$169.00M↓ | -$113.28M↑ | -$170.89M↓ | -$108.00M |
| Net Income | -$92.00M↑ | -$185.00M↓ | -$128.56M↑ | -$180.41M↓ | -$115.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, E...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.51B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
201.36%
Volume
Today's trading volume
5.91M
Recent News
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut Plan
In early September 2026, Ultragenyx Pharmaceutical announced that its Phase 3 Aspire trial of apazunersen (GTX-102) in Angelman syndrome failed to meet its primary and key secondary cognitive and functional endpoints, prompting a review of the program and planned significant expense reductions. On the same day, the FDA confirmed that Ultragenyx’s newly approved GENGLYCOS gene therapy for glycogen storage disease type Ia qualifies for a rare pediatric disease priority review voucher,...
Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback
Ultragenyx Pharmaceutical stock is under pressure after a multi year slide in returns, yet current market multiples still screen as expensive and the broader valuation checks send a mixed message. With fresh clinical setbacks alongside some positive data elsewhere in the pipeline, investors face conflicting signals about what the current price really reflects. Over the past 5 years the share price has fallen about 85%, which points to a sharp reset in market expectations for Ultragenyx...
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout
Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.
Why Did NIO, RARE, MCD Stocks Fall To 52-Week Lows?
NIO, Ultragenyx Pharmaceutical and McDonald's slipped to annual lows on Thursday amid company-related pressures and Wall Street pessimism around the stocks.
IONS Edges Up After-Hours On FDA’s Green Light For Neurology Drug After Being Dragged Down By Ultragenyx’s Failed Trial
Zanvastro is now approved for children and adults with Alexander disease, a rare and often fatal brain condition that affects fewer than one in a million people.